Indications
Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.
Composition
- Active substance
- dextromethorphan, quinidine
- International name (INN)
- dextromethorphan hydrobromide;quinidine sulfate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nuedexta
- Active substance
- dextromethorphan, quinidine
- ATC code
- N07XX59
- Group
- Nervous system
- Therapeutic area
- Neurobehavioral Manifestations
- Marketing authorisation holder